SANUWAVE Health (SNWV) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'SANUWAVE Health, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	37,561,515
Amendment Flag	'false	'
Entity Central Index Key	'0001417663	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash and cash equivalents	$333,830	$70,325
Accounts receivable - trade, net of allowance for doubtful accounts of $44,475 in 2013 and $44,124 in 2012	65,920	87,826
Inventory	243,758	292,665
Prepaid expenses	88,760	128,495
TOTAL CURRENT ASSETS	732,268	579,311
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation (Note 4)	18,006	32,842
OTHER ASSETS	11,384	11,358
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 5)	996,958	1,227,025
TOTAL ASSETS	1,758,616	1,850,536
CURRENT LIABILITIES	'	'
Accounts payable	390,040	555,898
Accrued expenses (Note 6)	833,641	721,916
Accrued employee compensation	428,233	534,659
Promissory notes (Note 7)	36,450	'
Interest payable, related parties (Note 9)	81,864	81,864
Capital lease payable, current portion (Note 13)	5,220	4,933
Liabilities related to discontinued operations	655,061	655,061
TOTAL CURRENT LIABILITIES	2,430,509	2,992,847
NON-CURRENT LIABILITIES	'	'
Notes payable, related parties (Note 9)	5,372,743	5,372,743
Capital lease payable, non-current portion (Note 13)	'	3,951
TOTAL NON-CURRENT LIABILITIES	5,372,743	5,376,694
TOTAL LIABILITIES	7,803,252	8,369,541
STOCKHOLDERS' DEFICIT	'	'
COMMON STOCK, par value $0.001, 150,000,000 shares authorized; 37,196,536 and 21,007,536 issued and outstanding in 2013 and 2012, respectively	37,197	21,008
ADDITIONAL PAID-IN CAPITAL	75,445,631	64,357,193
ACCUMULATED OTHER COMPREHENSIVE INCOME	7,312	13,116
ACCUMULATED DEFICIT	-81,534,776	-70,910,322
TOTAL STOCKHOLDERS' DEFICIT	-6,044,636	-6,519,005
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,758,616	1,850,536
Subscription Payable For Senior Secured Convertible Promissory Notes [Member]	'	'
CURRENT LIABILITIES	'	'
Subscription payable for senior secured convertible promissory notes (Note 8)	'	$438,516

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts (in Dollars)	$44,475	$44,124
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	5,000,000	5,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0
Common stock par value (in Dollars per share)	$0.00	$0.00
Common Stock, shares authorized (in Shares)	150,000,000	150,000,000
Common Stock, shares issued (in Shares)	37,196,536	21,007,536
Common Stock, shares outstanding (in Shares)	37,196,536	21,007,536

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
REVENUE	$148,421	$178,256	$510,272	$627,153
COST OF REVENUE	29,467	43,965	109,061	197,898
GROSS PROFIT	118,954	134,291	401,211	429,255
OPERATING EXPENSES	'	'	'	'
Research and development	775,717	440,193	1,744,935	1,391,634
General and administrative	1,151,709	977,859	3,160,749	3,252,127
Depreciation	4,854	4,973	14,836	15,313
Amortization	76,689	76,689	230,067	230,067
TOTAL OPERATING EXPENSES	2,008,969	1,499,714	5,150,587	4,889,141
OPERATING LOSS	-1,890,015	-1,365,423	-4,749,376	-4,459,886
OTHER INCOME (EXPENSE)	'	'	'	'
Loss on embedded conversion feature of Senior Secured Notes (Note 8)	-964,813	'	-2,373,813	'
Loss on extinguishment of Senior Secured Notes (Note 8)	-1,073,572	'	-1,073,572	'
Accretion of interest and interest expense on Senior Secured Notes (Note 8)	421,060	'	2,178,390	'
Interest expense, net	-88,772	-81,894	-256,472	-241,196
Gain on sale of fixed assets	'	'	7,500	'
Gain (loss) on foreign currency exchange	1,442	46	-331	-6,130
TOTAL OTHER INCOME (EXPENSE)	-2,546,775	-81,848	-5,875,078	-247,326
LOSS BEFORE INCOME TAXES	-4,436,790	-1,447,271	-10,624,454	-4,707,212
OTHER COMPREHENSIVE LOSS	'	'	'	'
Foreign currency translation adjustments	-1,829	4,623	-5,804	3,589
TOTAL COMPREHENSIVE LOSS	-4,438,619	-1,442,648	-10,630,258	-4,703,623
LOSS PER SHARE:	'	'	'	'
Net loss - basic (in Dollars per share)	($0.14)	($0.07)	($0.43)	($0.23)
Net loss - diluted (in Dollars per share)	($0.14)	($0.07)	($0.43)	($0.23)
Weighted average shares outstanding - basic (in Shares)	31,874,479	20,907,536	24,969,972	20,907,536
Weighted average shares outstanding - diluted (in Shares)	31,874,479	20,907,536	24,969,972	20,907,536
NET LOSS	-4,436,790	-1,447,271	-10,624,454	-4,707,212
Senior Secured Notes [Member]	'	'	'	'
OTHER INCOME (EXPENSE)	'	'	'	'
Accretion of interest and interest expense on Senior Secured Notes (Note 8)	($421,060)	'	($2,178,390)	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($10,624,454)	($4,707,212)
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Amortization	230,067	230,067
Depreciation	14,836	15,313
Change in allowance for doubtful accounts	352	-27,539
Stock-based compensation - employees, directors and advisors	683,382	719,732
Stock issued for consulting services	751,587	'
Loss on embedded conversion feature of Senior Secured Notes	2,373,813	'
Accrued interest	-2,178,390	'
Loss on extinguishment of Senior Secured Notes	1,073,572	'
Gain on sale of property and equipment	-7,500	'
Changes in assets - (increase)/decrease	'	'
Accounts receivable - trade	21,554	30,817
Inventory	48,907	101,386
Prepaid expenses	39,735	-40,157
Due from Pulse Veterinary Technologies, LLC	'	27,837
Other	-26	1
Changes in liabilities - increase/(decrease)	'	'
Accounts payable	-165,858	-354,299
Accrued employee compensation	-106,426	474,750
Accrued expenses	111,725	-16,995
NET CASH USED BY OPERATING ACTIVITIES	-3,374,894	-3,546,299
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Sale of property and equipment	7,500	'
Purchase of property and equipment	'	-2,011
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	7,500	-2,011
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from public offering, net	1,517,450	'
Proceeds from private placement	405,000	'
Proceeds from promissory notes	360,000	'
Proceeds from sale of capital stock - subscription agreement with related party	75,000	'
Proceeds from employee stock option exercise	37,917	'
Payments of principal on promissory notes	-325,000	'
Payments of principal on capital lease	-3,664	-3,399
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	3,636,703	-3,399
EFFECT OF EXCHANGE RATES ON CASH	-5,804	3,589
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	263,505	-3,548,120
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	70,325	3,909,383
CASH AND CASH EQUIVALENTS, END OF PERIOD	333,830	361,263
SUPPLEMENTAL INFORMATION	'	'
Cash paid for interest, related parties	242,904	242,903
Cash paid for capital lease interest	411	676
Senior Secured Notes [Member]	'	'
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Accrued interest	2,178,390	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from subscriptions payable for Senior Secured Notes	1,570,000	'
Promissory Notes [Member]	'	'
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Accrued interest	$1,450	'

Note_1_Nature_of_Business

Note 1 - Nature of Business	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.            Nature of the Business
	SANUWAVE Health, Inc. and subsidiaries (the “Company”) is a shockwave technology company using a patented system of noninvasive, high-energy, acoustic shockwaves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shockwaves to solicit a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the demaPACE® device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers with possible FDA approval in 2015 subject to submission of satisfactory clinical study results.
	The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. The Company is not currently marketing any commercial products in the United States. Revenue is from sales of the European Conformity Marking (“CE Mark”) devices and accessories in Europe, Canada and Asia/Pacific.
	In addition, there are license/partnership opportunities for the Company’s shockwave technology for non-medical uses, including energy, water, food and industrial markets.

Note_2_Going_Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2013
Policy Text Block [Abstract]	'
Liquidity Disclosure [Policy Text Block]	'
	2.            Going concern
	As of September 30, 2013, the Company had cash and cash equivalents of $333,830 and negative working capital of $1,698,241. For the nine months ended September 30, 2013 and 2012, the net cash used by operating activities was $3,374,894 and $3,546,299, respectively. The Company incurred a net loss of $10,624,454 for the nine months ended September 30, 2013 and a net loss of $6,401,494 for the year ended December 31, 2012. Since inception, the Company has experienced recurring losses from operations and had an accumulated deficit of $81,534,776 at September 30, 2013. As a result, there is substantial doubt as to the Company’s ability to continue as a going concern.
	On September 30, 2013, the Company, in conjunction with an offering of securities (the “Private Offering”) of the Company pursuant to an exemption from registration under the Securities Act of 1933, as amended (the “Act”), issued 675,000 units (as described below) to certain “accredited investors,” as that term is defined in the Securities and Exchange Commission’s (the “SEC”) Rule 501 under the Act, for an aggregate total purchase price of $405,000. In addition, in October 2013, after the end of the third quarter of 2013, in conjunction with the Private Offering, the Company issued an additional 201,979 units for an aggregate total purchase price of $121,187. Each unit was sold at a purchase price of $0.60 per unit with each “unit” consisting of; (i) one share of common stock and (ii) a five-year warrant to purchase one share of common stock at an exercise price of $0.85.
	On July 25, 2013, the Company consummated a public offering (the “Public Offering”) of an aggregate of 3,006,818 units, with each unit consisting of one share of Company common stock and a warrant to purchase one-half share of a common stock, resulting in warrants to purchase up to 1,503,409 shares of common stock.  The price per unit was $0.55 resulting in gross proceeds of $1,653,750. The Company received net proceeds, after payment of the placement agent’s fees, of $1,517,450. The units separated immediately and the common stock and warrants were issued separately. The warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance.
	The continuation of the Company’s business is dependent upon raising additional capital in the fourth quarter of 2013. Management’s plans are to obtain additional capital in the fourth quarter of 2013 through the issuance of common stock and/or other debt or equity securities and the Company has engaged financial advisors to assist with this process. The Company’s cash and cash equivalents at September 30, 2013, combined with the proceeds from the Private Offering in October 2013, and/or amounts received on the Company’s subscription agreement with an affiliated shareholder (see Note 13) is expected to support the Company’s operations through the completion, in the fourth quarter of 2013, of an anticipated capital raise as discussed above. Management expects the Company’s monthly use of cash in the fourth quarter of 2013 and the first half of 2014 will be approximately $575,000 to $625,000 as the Company devotes substantial resources to the patient enrollment phase of the supplemental Phase III clinical trial for the dermaPACE device to treat diabetic foot ulcers. The Company estimates the direct cost of the dermaPACE clinical trial will be approximately $3,800,000 through 2014.
	The Company may raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt, an investment by a strategic partner in a specific clinical indication or market opportunity, or by selling all or a portion of the Company’s assets (or some combination of the foregoing). If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” in this Form 10-Q.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	3.             Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X.  Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.  Operating results for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2013.
	The condensed consolidated balance sheet at December 31, 2012 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements.
	Significant Accounting Policies
	For further information and a summary of significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on March 26, 2013.
	Fair Value Measurements
	The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable - trade, accounts payable, accrued expenses and promissory notes approximate fair value due to the short-term nature of these instruments.
	The Company has adopted ASC 820-10, Fair Value Measurements (formerly SFAS No. 157), which defines fair value, establishes a framework for measuring fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
	Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
	Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions.
	The following table sets forth a summary of changes in the fair value of the derivative liability for the three and nine months ended September 30, 2013:
		Embedded
		Conversion
		Feature of
		Senior Secured
		Notes
	Balance at December 31, 2012	$	-
	New issuances		4,908,000
	Change in fair value		829,000
	Balance at March 31, 2013		5,737,000
	Change in fair value		(2,328,000	)
	Balance at June 30, 2013		3,409,000
	Conversion to equity		(3,409,000	)
	Balance at September 30, 2013	$	-
	The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities, as amended and interpreted. ASC 815 requires that the Company recognize all derivatives on the balance sheet at fair value. On March 8, 2013, the Company completed an offering and issued Senior Secured Notes that contained an embedded conversion feature which was accounted for as a derivative liability. In recording this derivative liability, $2,000,000 was recorded as a debt discount and the remaining value, along with the gains (losses) resulting from the changes in the fair value of the derivative instruments, was recorded in the “gain (loss) on embedded conversion feature of Senior Secured Notes” in the accompanying condensed consolidated statements of comprehensive loss. The fair value of the embedded conversion feature was determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate.
	The Company’s notes payable, related parties, consist of $5,372,743 of principal at September 30, 2013 and December 31, 2012. Interest accrues on the notes at a rate of 6% per annum. The fair value was determined using estimated future cash flows discounted at current rates, which is a Level 3 measurement. The estimated fair value of the Company’s notes payable, related parties was $4,775,110 and $4,545,620 at September 30, 2013 and December 31, 2012, respectively.
	Recently Issued Accounting Standards
	New accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.
	In February 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-02, which amends the guidance in Accounting Standards Codification (“ASC”) 220 on Comprehensive Income. Under the revised guidance, companies are required to provide information about the amounts reclassified out of accumulated other comprehensive income (“AOCI”) by component. In addition, companies are required to present, either on the face of the statement where net income (loss) is presented or in the notes, the effects on the line items of net income (loss) of significant amounts reclassified out of AOCI but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income (loss) in its entirety in the same reporting period. This amended guidance is to be applied prospectively and is effective for reporting periods (interim and annual) beginning after December 15, 2012 for public companies, with early adoption permitted. The Company adopted the revised guidance January 1, 2013, and reported significant items reclassified out of AOCI in the notes to the condensed consolidated financial statements (see Note 16).

Note_4_Property_and_equipment

Note 4 - Property and equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	4.             Property and equipment
	Property and equipment consists of the following:
		September 30,			December 31,
		2013			2012
	Machines and equipment	$	233,793		$	233,793
	Office and computer equipment		179,349			179,349
	Software		41,872			41,872
	Furniture and fixtures		25,679			25,679
	Vehicles		-			22,531
	Other assets		2,446			2,446
	Total		483,139			505,670
	Accumulated depreciation		(465,133	)		(472,828	)
	Net property and equipment	$	18,006		$	32,842
	The aggregate depreciation related to property and equipment charged to operations was $4,854 and $4,973 for the three months ended September 30, 2013 and 2012, respectively, and $14,836 and $15,313 for the nine months ended September 30, 2013 and 2012, respectively.

Note_5_Intangible_assets

Note 5 - Intangible assets	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	5.            Intangible assets
	Intangible assets consist of the following:
		September 30,			December 31,
		2013			2012
	Patents, at cost	$	3,502,135		$	3,502,135
	Less accumulated amortization		(2,505,177	)		(2,275,110	)
	Net intangible assets	$	996,958		$	1,227,025
	The aggregate amortization charged to operations was $76,689 and $76,689 for the three months ended September 30, 2013 and 2012, respectively, and $230,067 and $230,067 for the nine months ended September 30, 2013 and 2012, respectively.

Note_6_Accrued_expenses

Note 6 - Accrued expenses	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6.            Accrued expenses
	Accrued expenses consist of the following:
		September 30,		December 31,
		2013		2012
	Accrued executive severance	$	400,000	$	542,269
	Accrued clinical expenses		206,489		-
	Accrued audit and tax preparation		73,700		102,600
	Accrued legal professional fees		44,500		23,519
	Accrued board of director fees		25,333		-
	Accrued other		83,619		53,528
		$	833,641	$	721,916

Note_7_Promissory_notes

Note 7 - Promissory notes	9 Months Ended
	Sep. 30, 2013
Promissory Notes [Abstract]	'
Promissory Notes [Text Block]	'
	7.            Promissory notes
	The Company issued short-term, unsecured promissory notes, in the aggregate principal amount of $360,000, between May 14, 2013 and July 9, 2013, to certain existing shareholders. The promissory notes accrue interest at a rate of 18% per annum and, together with all accrued and unpaid interest, are due and payable 179 days from their individual issuance date. In the event that the promissory notes are not paid in full within three business days of their respective maturity dates, then, from and after such maturity date and until payment in full, interest will accrue on the outstanding principal balance at the rate of 25% per annum.
	Joseph Chiarelli, the Company’s Chief Executive Officer, purchased promissory notes in the offering in the principal amount of $35,000. David N. Nemelka, the brother of John F. Nemelka, who is a member of the Company’s board of directors, purchased promissory notes in the offering in the principal amount of $100,000.
	On August 1, 2013, at the request of the promissory note holders, the Company repaid $325,000 of the original principal value of the notes in full, along with accrued interest of $10,664. At September 30, 2013, there was one promissory note outstanding for $36,450, including accrued interest, payable to Joseph Chiarelli.

Note_8_18_Senior_Secured_Conve

Note 8 - 18% Senior Secured Convertible Promissory Notes	9 Months Ended
	Sep. 30, 2013
Secured Convertible Promissory Notes [Abstract]	'
Secured Convertible Promissory Notes [Text Block]	'
	8.            18% Senior secured convertible promissory notes
	During the period from November 2012 through March 8, 2013, the Company entered subscriptions payable for 18% senior secured convertible promissory notes (the “Senior Secured Notes”) from select accredited investors. The Company completed the offering and issued an aggregate $2,000,000 in Senior Secured Notes on March 8, 2013.
	The Senior Secured Notes had a six month term from the subscription date and the note holders could convert into Company common stock at anytime during the term at a conversion price of $0.20 per share – the market price at the time the subscription agreement was written. Upon the consummation of a qualified financing and/or technology license, as defined in the Senior Secured Note agreements, as amended, of $4,000,000 or more by the Company, the principal and interest on the Senior Secured Notes would automatically convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing and/or technology license, reduced by a discount of 20%, and (ii) $0.20 per share - the market price at the time the subscription agreement was written. The note holders (the “Holders”) would also receive, if any are issued, warrants or any other securities issued in a qualified financing and/or technology license on similar terms to the qualified financing and/or technology license. The Senior Secured Notes were secured by the tangible and intangible assets of the Company.
	On July 31, 2013, all of the Holders of the Senior Secured Notes voluntarily converted all of the outstanding principal and interest of the Senior Secured Notes into Company common stock. The aggregate outstanding amount of principal and interest on the Senior Secured Notes at July 31, 2013 of $2,186,906 was converted into 10,934,533 shares of restricted Company common stock at the conversion price of $0.20 per share - the market price at the time the subscription agreement was written - pursuant to the Senior Secured Note agreements. In return for the Holders’ voluntarily converting the outstanding Senior Secured Notes on or before July 31, 2013, the Company agreed to issue to the Holders warrants to purchase an aggregate total of 1,988,095 shares of Company common stock. The warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance. In July 2013, the Company recorded a loss from extinguishment of debt of $1,073,572, which was the estimated fair value of the warrants issued to the Holders on the date of exchange calculated using the Black-Scholes pricing model.
	Kevin A. Richardson, II, chairman of the board of directors of the Company, converted an aggregate balance of $64,500 of the Senior Secured Notes and received 322,500 shares of Company common stock and 58,635 warrants in the foregoing transaction.
	The conversion feature embedded in the Senior Secured Notes was accounted for as a derivative liability, and resulted in the creation at issuance of a discount to the carrying amount of the debt in the amount of $2,000,000, which was amortized as additional interest expense using the straight-line method over the term of the Senior Secured Notes (the Company determined that using the straight-line method of amortization did not yield a materially different amortization schedule than the effective interest method). The embedded conversion feature was recorded at fair value and marked to market at each period, with the resulting change in fair value being recorded in the “loss on embedded conversion feature of Senior Secured Notes” in the accompanying condensed consolidated statements of comprehensive loss.
	Interest expense on the Senior Secured Notes, including amortization of the debt discount, totaled $421,060 and $2,178,390 for the three and nine months ended September 30, 2013, respectively.

Note_9_Notes_Payable_Related_P

Note 9 - Notes Payable, Related Parties	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	9.             Notes payable, related parties
	The notes payable, related parties consist of the following:
		Sepetember 30,		December 31,
		2013		2012
	Notes payable, unsecured, payable to HealthTronics, Inc., a shareholder of the Company	$	5,372,743	$	5,372,743
	Less current portion		-		-
	Non-current portion	$	5,372,743	$	5,372,743
	The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest is paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal is due August 1, 2015. Accrued interest currently payable totaled $81,864 and $81,864 at September 30, 2013 and December 31, 2012, respectively.
	Interest expense on notes payable to related parties totaled $81,864 and $81,864 for the three months ended September 30, 2013 and 2012, respectively, and $242,904 and $242,903 for the nine months ended September 30, 2013 and 2012, respectively.

Note_10_Income_taxes

Note 10 - Income taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	10.          Income taxes
	The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2006.
	At September 30, 2013, the Company had federal net operating loss (“NOL”) carryforwards of $53,648,527 for tax years through the year ended December 31, 2012, that will begin to expire in 2025. The use of deferred tax assets, including federal net operating losses, is limited to future taxable earnings. Based on the required analysis of future taxable income under the provisions of ASC 740, Income Taxes (formerly SFAS No. 109), the Company’s management believes that there is not sufficient evidence at September 30, 2013 indicating that the results of operations will generate sufficient taxable income to realize the net deferred tax asset in years beyond 2013. As a result, a valuation allowance was provided for the entire net deferred tax asset related to future years, including NOL carryforwards.
	The Company’s ability to use its NOL carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its NOL carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which NOL carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its NOL carryforwards for federal income tax purposes.

Note_11_Equity_Transactions

Note 11 - Equity Transactions	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	11.          Equity transactions
	2013 Private Offering
	On September 30, 2013, the Company, in conjunction with an offering of securities (previously defined as the “Private Offering”) of the Company pursuant to an exemption from registration under the Act, issued 675,000 units (as described below) to certain “accredited investors,” as that term is defined in SEC Rule 501 under the Act, for an aggregate total purchase price of $405,000. In addition, in October 2013, after the end of the third quarter of 2013, in conjunction with the Private Offering, the Company issued an additional 201,979 units for an aggregate total purchase price of $121,187. Each unit was sold to the accredited investors at a purchase price of $0.60 per unit. Each “unit” in the Private Offering consists of; (i) one share of common stock and (ii) a five-year common stock purchase warrant to purchase one share of common stock, at an exercise price of $0.85. The warrants are callable by the Company if the average share price of common stock of the Company is at or above $1.40 for a twenty day period.
	Kevin A. Richardson II, who is the chairman of the board of directors of the Company, and Joseph Chiarelli, who is the Chief Executive Officer of the Company, and Michael M. Nemelka, who is the brother of John F. Nemelka, a member of the board of directors of the Company, purchased units in the Private Offering.
	2013 Public Offering
	On July 25, 2013, the Company consummated a public offering (as previously defined, the “Public Offering”) of an aggregate of 3,006,818 units, with each unit consisting of one share of common stock and a warrant to purchase one-half share of a common stock, resulting in warrants to purchase up to 1,503,409 shares of common stock.  The price per unit was $0.55 resulting in gross proceeds of $1,653,750. The Company received net proceeds, after payment of the placement agent’s fees, of $1,517,450. The units separated immediately and the common stock and warrants were issued separately. The warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance.
	Consulting Agreements
	On February 25, 2013, the Company issued to a consultant 2,000,000 warrants to purchase the Company’s common stock at $0.35 per share. The five year warrants vest 300,000 on the date of grant and 1,700,000 upon the completion of a $5,000,000, or greater, capital raise on or prior to June 8, 2013 (see Note 12). A capital raise was not completed for the requisite amount and the 1,700,000 warrants expired by their terms on June 8, 2013. The Company recorded the underlying cost of the 300,000 warrants as a cost of the Public Offering.
	In February 2013, the Company entered into a consulting agreement with a consultant to assist the Company with its strategy for raising additional capital for which a portion of the fee for the services performed is common stock and warrants. The Company issued 100,000 shares of common stock under this agreement in February 2013. The fair value of the common stock of $35,000, based upon the closing market price of the Company’s common stock at the date the common stock was issued, was recorded as consulting expense for the three months ended March 31, 2013. In addition, the Company committed to issue to the consultant 1,000,000 warrants to purchase common stock at an exercise price of $0.35 per share with a term of five years upon consummation by the Company of an qualified offering (as defined in the consulting agreement) resulting in gross proceeds to the Company of no less than $4,000,000. This agreement expired on July 29, 2013 and no warrants were earned or issued pursuant to the terms of the agreement.
	In February 2013, the Company entered into two consulting agreements for which a portion of the fee for the services performed is paid with common stock. In August and September 2013, the Company entered into two additional consulting agreements for which a portion of the fee for the services performed is paid with common stock. The Company issued 542,000 and 934,000 shares of common stock under these agreements for the three and nine months ended September 30, 2013, respectively. The fair value of the common stock of $313,880 and $622,760, based upon the closing market price of the Company’s common stock at the dates the common stock was issued, was recorded as consulting expense for the three and nine months ended September 30, 2013, respectively.

Note_12_Warrants

Note 12 - Warrants	9 Months Ended
	Sep. 30, 2013
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding [Abstract]	'
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	'
	12.         Warrants
	A summary of the warrant activity as of September 30, 2013 and December 31, 2012, and the changes during the three and nine months ended September 30, 2013, is presented as follows:
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Outstanding as of
	31-Dec-12		1,106,627		1,106,627		1,950,167			3,576,737		-			-		-		-
	Issued		-		-		-			-		2,000,000			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(1,950,167	)		-		-			-		-		-
	Outstanding as of
	31-Mar-13		1,106,627		1,106,627		-			3,576,737		2,000,000			-		-		-
	Issued		-		-		-			-		-			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		-			-		-			-		-		-
	Outstanding as of
	30-Jun-13		1,106,627		1,106,627		-			3,576,737		2,000,000			-		-		-
	Issued		-		-		-			-		-			1,503,409		1,988,095		675,000
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		-			-		(1,700,000	)		-		-		-
	Outstanding as of
	30-Sep-13		1,106,627		1,106,627		-			3,576,737		300,000			1,503,409		1,988,095		675,000
	A summary of the warrant exercise price per share and expiration date is presented as follows:
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Exercise price/share	$	4	$	8	$	2		$	4	$	0.35		$	0.8	$	0.8	$	0.85
	Expiration Date	Sep-14		September		Jan-13			Apr-16		Feb-18			Jul-18		Jul-18		Sep-18
				2014
	The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company.
	As discussed in Note 11 above, on February 25, 2013, the Company issued 2,000,000 warrants to a consultant to purchase the Company’s common stock at $0.35 per share. The five year warrants vest 300,000 on the date of grant and 1,700,000 upon the completion of a $5,000,000, or greater, capital raise on or prior to June 8, 2013. A capital raise was not completed for the requisite amount and the 1,700,000 warrants expired by their terms. The Company recorded the underlying cost of the 300,000 warrants as a cost of the Public Offering.

Note_13_Commitments_and_contin

Note 13 - Commitments and contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	13.          Commitments and contingencies
	Subscription agreement
	On November 27, 2012, the Company and David N. Nemelka (the “Subscriber”), the brother of John F. Nemelka, a member of the Company’s board of directors, entered into a subscription agreement (the “Subscription Agreement”) whereby the Subscriber has agreed to purchase from the Company, and the Company has agreed to sell and issue, a total of 4,000,000 shares of the Company’s unregistered common stock at a purchase price equal to $0.25 per share, for an aggregate sales price of $1,000,000 (the “Purchase Price”). The shares are subject to piggy-back registration rights if the Company files a registration statement for an offering of securities.
	The Purchase Price shall be payable to the Company as follows: (i) $50,000 on or before January 31, 2013; (ii) $50,000 on or before February 15, 2013; and (iii) the balance of $900,000 on or before May 27, 2014 (the “Outside Due Date”). The Subscriber may make payments of the Purchase Price at his discretion in minimum installments of $100,000 each, until the Outside Due Date.
	In the event that at any time after February 15, 2013, the Company’s total available cash should be less than $100,000, the Subscriber shall, upon demand of the Company, pay to the Company $100,000 of the then outstanding balance of the Purchase Price, which payment shall be due within thirty (30) days of the demand. There is no limit on the number of demands that the Company may make pursuant to this provision of the Subscription Agreement, provided, however, that in no event shall the Company provide more than one notice of demand for payment in any thirty (30) day period.
	As of September 30, 2013, the Subscriber had paid the Company $100,000 and was issued 400,000 shares of unregistered common stock of the Company. The Company will record the additional $900,000 and issue the corresponding 3,600,000 shares of common stock in the periods in which the Purchase Price is received.
	Operating Leases
	Rent expense for the three months ended September 30, 2013 and 2012, was $22,531 and $68,462, respectively, and $76,508 and $238,712 for the nine months ended September 30, 2013 and 2012, respectively.
	Capital Leases
	The Company leases certain office equipment under an agreement classified as a capital lease. The leased assets serve as security for the lease. The accumulated depreciation of such equipment at September 30, 2013 and December 31, 2012 totaled $10,106 and $6,468, respectively. The net book value of such equipment at September 30, 2013 and December 31, 2012 totaled $4,446 and $8,085, respectively.
	Litigation
	The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note_14_401k_plan

Note 14 - 401(k) plan	9 Months Ended
	Sep. 30, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'
Description of Defined Contribution Pension and Other Postretirement Plans	'
	14.          401(k) plan
	The Company sponsors a 401(k) plan that covers all employees who meet the eligibility requirements. The Company amended the 401(k) plan to make the Company matching contribution discretionary and discontinued the Company match effective February 1, 2012. The Company did not contribute to the plan for the three months ended September 30, 2013 and 2012, respectively. The Company contributed $0 and $9,664 to the plan for the nine months ended September 30, 2013 and 2012, respectively.

Note_15_Stockbased_compensatio

Note 15 - Stock-based compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	15.          Stock-based compensation
	On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to four years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. At December 31, 2012, the Stock Incentive Plan reserved 5,000,000 shares of common stock for grant. On February 21, 2013, the Stock Incentive Plan was amended to reserve a total of 8,500,000 shares of common stock for grant.
	On September 3, 2013, the Company granted 100,000 options to the new member of the board of directors at an exercise price of $0.65 per share. The options vested at the date of grant and have a ten year term. Using the Black-Scholes option pricing model, management has determined that the options had a weighted average fair value per share of $0.60 resulting in total compensation of $60,000. Compensation cost was recognized at grant date.
	On February 21, 2013, the Company, by mutual agreement with all the active employees and directors of the Company, cancelled options granted to the active employees in the year ended December 31, 2011 and prior which totaled 1,113,644 shares of common stock at an average exercise price of $2.92. In exchange for these options, the active employees and directors received new options to purchase 2,243,644 shares of common stock at an exercise price of $0.35 per share. Using the Black-Scholes option pricing model, management has determined that the options at the grant date, net of the value of the cancelled options as of the date of cancellation, had an average fair value per share of $0.223 resulting in total compensation of $499,621. Compensation cost will be recognized over the requisite service period.
	On February 21, 2013, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.35 per share in place of an annual cash consulting fee for calendar year 2013. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.63 resulting in compensation expense of $63,000. Compensation cost will be recognized over the calendar year 2013.
	On February 25, 2013, Joseph Chiarelli joined the Company to serve as the Chief Executive Officer and a director of the Company. Mr. Chiarelli was granted options to purchase 2,250,000 shares of the Company’s common stock at an exercise price of $0.35 per share. The options vest and become exercisable in five installments as follows: (i) 375,000 vested at grant; (ii) 375,000 vest upon the Company completing a financing resulting in gross proceeds to the Company of no less than $5,000,000 at a price per share of not less than $0.35; (iii) 375,000 upon the execution by the Company of a license or distribution agreement from which the Company is entitled to receive gross proceeds of no less than $1,000,000 and the Company has received payments of at least $250,000; (iv) 375,000 vest upon receipt by the Company of FDA approval for the use of dermaPACE; and (v) 750,000 vest in the event the Company achieves the milestones (i), (ii), (iii) and (iv) above during the initial two year term and the term is not extended by the Company. Using the Black-Scholes option pricing model, management has determined that the options had an average fair value per share of $0.207 resulting in total compensation of $465,000. Compensation cost will be recognized over the requisite service period.
	On March 8, 2012, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.44 per share in place of an annual cash consulting fee for calendar year 2012. Using the Black-Scholes option pricing model, management has determined that the options granted had a fair value per share of $0.27 resulting in total compensation of $27,250. Compensation cost was recognized over the calendar year 2012.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the three months ended September 30, 2013 and 2012:
		2013			2012
	Weighted average expected life in years		5			5.2
	Weighted average risk free interest rate		1.68	%		0.95	%
	Weighted average volatility		149	%		75	%
	Forfeiture rate		0	%		0	%
	Expected dividend yield		0	%		0	%
	The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. Since there is a limited trading history for the Company’s common stock, the expected volatility is based on a combination of historical data from companies similar in size, value and trading history for the Company’s common stock. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Management estimates pre-vesting forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. The expected dividend yield is based on historical dividend experience, however, since inception the Company has not declared dividends.
	The Company recognized as compensation cost for all outstanding stock options granted to employees, directors and advisors, $175,987 and $217,686 for the three months ended September 30, 2013 and 2012, respectively, and $683,382 and $719,732 for the nine months ended September 30, 2013 and 2012, respectively.
	A summary of option activity as of September 30, 2013 and December 31, 2012, and the changes during the three and nine months ended September 30, 2013, is presented as follows:
		Options			Weighted
					Average
					Exercise Price
					per share
	Outstanding as of December 31, 2012		5,229,330		$	2.25
	Granted		4,593,644		$	0.35
	Exercised		-		$	-
	Cancelled		(1,113,644	)	$	2.92
	Forfeited or expired		(105,000	)	$	2.93
	Outstanding as of March 31, 2013		8,604,330		$	1.14
	Granted		-		$	-
	Exercised		(108,334	)	$	0.35
	Cancelled		-		$	-
	Forfeited or expired		(229,166	)	$	(0.34	)
	Outstanding as of June 30, 2013		8,266,830		$	1.17
	Granted		100,000		$	0.65
	Exercised		-		$	-
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of September 30, 2013		8,366,830		$	1.17
	Exercisable		4,887,738		$	1.76
	The weighted average remaining contractual term for outstanding and exercisable stock options was 7.1 years as of September 30, 2013, and 6.6 years as of December 31, 2012.
	A summary of the Company’s nonvested options as of September 30, 2013 and December 31, 2012, and changes during the three and nine months ended September 30, 2013, is presented as follows:
		Options			Weighted
					Average
					Exercise Price
					per share
	Outstanding as of December 31, 2012		508,750		$	0.66
	Granted		4,593,644		$	0.35
	Vested		(1,180,386	)	$	0.41
	Cancelled		(43,750	)	$	2.87
	Forfeited or expired		(7,500	)	$	5.25
	Outstanding as of March 31, 2013		3,870,758		$	0.33
	Granted		-		$	-
	Vested		(137,500	)	$	0.24
	Cancelled		-		$	-
	Forfeited or expired		(229,166	)	$	0.34
	Outstanding as of June 30, 2013		3,504,092		$	0.34
	Granted		100,000		$	0.65
	Vested		(125,000	)	$	0.59
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of September 30, 2013		3,479,092		$	0.34

Note_16_Changes_in_other_compr

Note 16 - Changes in other comprehensive loss	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	16.          Changes in other comprehensive loss
	The amounts recognized in other comprehensive loss for the three and nine months ended September 30, 2013 were as follows:
		Currency			Total
		Translations
	Balance, at December 31, 2012	$	13,116		$	13,116
	Other comprehensive loss before reclassifications		(6,925	)		(6,925	)
	Amounts reclassified from AOCI		-			-
	Net change in other comprehensive loss		(6,925	)		(6,925	)
	Balance, at March 31, 2013		6,191			6,191
	Other comprehensive income		2,950			2,950
	Balance, at June 30, 2013		9,141			9,141
	Other comprehensive loss		(1,829	)		(1,829	)
	Balance, at September 30, 2013	$	7,312		$	7,312

Note_17_Earnings_Loss_Per_Shar

Note 17 - Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	17.          Earnings (loss) per share
	The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share (formerly SFAS No. 128, Earnings Per Share).  Under the provisions of ASC 260, basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of shares of common stock outstanding for the period.  Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share.
	As a result of the net loss for the three and nine months ended September 30, 2013 and 2012, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 18,623,325 shares and 14,189,481 shares at September 30, 2013 and 2012, respectively.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Embedded
		Conversion
		Feature of
		Senior Secured
		Notes
	Balance at December 31, 2012	$	-
	New issuances		4,908,000
	Change in fair value		829,000
	Balance at March 31, 2013		5,737,000
	Change in fair value		(2,328,000	)
	Balance at June 30, 2013		3,409,000
	Conversion to equity		(3,409,000	)
	Balance at September 30, 2013	$	-

Note_4_Property_and_equipment_

Note 4 - Property and equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Machines and equipment	$	233,793		$	233,793
	Office and computer equipment		179,349			179,349
	Software		41,872			41,872
	Furniture and fixtures		25,679			25,679
	Vehicles		-			22,531
	Other assets		2,446			2,446
	Total		483,139			505,670
	Accumulated depreciation		(465,133	)		(472,828	)
	Net property and equipment	$	18,006		$	32,842

Note_5_Intangible_assets_Table

Note 5 - Intangible assets (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Patents, at cost	$	3,502,135		$	3,502,135
	Less accumulated amortization		(2,505,177	)		(2,275,110	)
	Net intangible assets	$	996,958		$	1,227,025

Note_6_Accrued_expenses_Tables

Note 6 - Accrued expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		September 30,		December 31,
		2013		2012
	Accrued executive severance	$	400,000	$	542,269
	Accrued clinical expenses		206,489		-
	Accrued audit and tax preparation		73,700		102,600
	Accrued legal professional fees		44,500		23,519
	Accrued board of director fees		25,333		-
	Accrued other		83,619		53,528
		$	833,641	$	721,916

Note_9_Notes_Payable_Related_P1

Note 9 - Notes Payable, Related Parties (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		Sepetember 30,		December 31,
		2013		2012
	Notes payable, unsecured, payable to HealthTronics, Inc., a shareholder of the Company	$	5,372,743	$	5,372,743
	Less current portion		-		-
	Non-current portion	$	5,372,743	$	5,372,743

Note_12_Warrants_Tables

Note 12 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Outstanding as of
	31-Dec-12		1,106,627		1,106,627		1,950,167			3,576,737		-			-		-		-
	Issued		-		-		-			-		2,000,000			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		(1,950,167	)		-		-			-		-		-
	Outstanding as of
	31-Mar-13		1,106,627		1,106,627		-			3,576,737		2,000,000			-		-		-
	Issued		-		-		-			-		-			-		-		-
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		-			-		-			-		-		-
	Outstanding as of
	30-Jun-13		1,106,627		1,106,627		-			3,576,737		2,000,000			-		-		-
	Issued		-		-		-			-		-			1,503,409		1,988,095		675,000
	Exercised		-		-		-			-		-			-		-		-
	Expired		-		-		-			-		(1,700,000	)		-		-		-
	Outstanding as of
	30-Sep-13		1,106,627		1,106,627		-			3,576,737		300,000			1,503,409		1,988,095		675,000
Schedule of Warrant Exercise Price and Expiration Date [Table Text Block]	'
		Class A		Class B		Class D			Class E		Class F			Class G		Class H		Class I
		Warrants		Warrants		Warrants			Warrants		Warrants			Warrants		Warrants		Warrants
	Exercise price/share	$	4	$	8	$	2		$	4	$	0.35		$	0.8	$	0.8	$	0.85
	Expiration Date	Sep-14		September		Jan-13			Apr-16		Feb-18			Jul-18		Jul-18		Sep-18
				2014

Note_15_Stockbased_compensatio1

Note 15 - Stock-based compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		2013			2012
	Weighted average expected life in years		5			5.2
	Weighted average risk free interest rate		1.68	%		0.95	%
	Weighted average volatility		149	%		75	%
	Forfeiture rate		0	%		0	%
	Expected dividend yield		0	%		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Options			Weighted
					Average
					Exercise Price
					per share
	Outstanding as of December 31, 2012		5,229,330		$	2.25
	Granted		4,593,644		$	0.35
	Exercised		-		$	-
	Cancelled		(1,113,644	)	$	2.92
	Forfeited or expired		(105,000	)	$	2.93
	Outstanding as of March 31, 2013		8,604,330		$	1.14
	Granted		-		$	-
	Exercised		(108,334	)	$	0.35
	Cancelled		-		$	-
	Forfeited or expired		(229,166	)	$	(0.34	)
	Outstanding as of June 30, 2013		8,266,830		$	1.17
	Granted		100,000		$	0.65
	Exercised		-		$	-
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of September 30, 2013		8,366,830		$	1.17
	Exercisable		4,887,738		$	1.76
Schedule of Other Share-based Compensation, Activity [Table Text Block]	'
		Options			Weighted
					Average
					Exercise Price
					per share
	Outstanding as of December 31, 2012		508,750		$	0.66
	Granted		4,593,644		$	0.35
	Vested		(1,180,386	)	$	0.41
	Cancelled		(43,750	)	$	2.87
	Forfeited or expired		(7,500	)	$	5.25
	Outstanding as of March 31, 2013		3,870,758		$	0.33
	Granted		-		$	-
	Vested		(137,500	)	$	0.24
	Cancelled		-		$	-
	Forfeited or expired		(229,166	)	$	0.34
	Outstanding as of June 30, 2013		3,504,092		$	0.34
	Granted		100,000		$	0.65
	Vested		(125,000	)	$	0.59
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of September 30, 2013		3,479,092		$	0.34

Note_16_Changes_in_other_compr1

Note 16 - Changes in other comprehensive loss (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Currency			Total
		Translations
	Balance, at December 31, 2012	$	13,116		$	13,116
	Other comprehensive loss before reclassifications		(6,925	)		(6,925	)
	Amounts reclassified from AOCI		-			-
	Net change in other comprehensive loss		(6,925	)		(6,925	)
	Balance, at March 31, 2013		6,191			6,191
	Other comprehensive income		2,950			2,950
	Balance, at June 30, 2013		9,141			9,141
	Other comprehensive loss		(1,829	)		(1,829	)
	Balance, at September 30, 2013	$	7,312		$	7,312

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

Sep. 30, 2013

Jul. 25, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jul. 31, 2013

Feb. 25, 2013

Dec. 31, 2011

Oct. 31, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Subsequent Event [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Minimum [Member]

Maximum [Member]

Note 2 - Going Concern (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents, at Carrying Value

$333,830

'

'

$333,830

$361,263

$333,830

$361,263

$70,325

'

'

$3,909,383

'

'

'

'

Working Capital

1,698,241

'

'

1,698,241

'

1,698,241

'

'

'

'

'

'

'

'

'

Net Cash Provided by (Used in) Operating Activities

'

'

'

'

'

-3,374,894

-3,546,299

'

'

'

'

'

'

575,000

625,000

Net Income (Loss) Attributable to Parent

'

'

'

-4,436,790

-1,447,271

-10,624,454

-4,707,212

-6,401,494

'

'

'

'

'

'

'

Retained Earnings (Accumulated Deficit)

-81,534,776

'

'

-81,534,776

'

-81,534,776

'

-70,910,322

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

675,000

3,006,818

100,000

'

'

400,000

'

'

'

'

'

201,979

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

405,000

1,653,750

'

'

'

405,000

'

'

'

'

'

121,187

'

'

'

Warrants Price Per Unit (in Dollars per Item)

'

0.8

'

'

'

'

'

'

'

'

'

0.6

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

0.55

0.35

'

'

'

'

'

0.8

0.35

'

0.85

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

1,503,409

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance of Private Placement Net (in Dollars)

'

1,517,450

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exercisable Term

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Direct Operating Costs

'

'

'

'

'

'

'

'

'

'

'

'

$3,800,000

'

'

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Mar. 08, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'
Debt Instrument, Unamortized Discount	$2,000,000	$2,000,000	'
Notes Payable, Related Parties	5,372,743	'	5,372,743
Related Party Transaction, Rate	6.00%	'	'
Notes Payable, Fair Value Disclosure	$4,775,110	'	$4,545,620

Note_3_Summary_of_Significant_3

Note 3 - Summary of Significant Accounting Policies (Details) - Summary of Changes in the Fair Value of the Derivative Liability (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Summary of Changes in the Fair Value of the Derivative Liability [Abstract]	'	'	'
Balance at	$3,409,000	$5,737,000	'
New issuances	'	'	4,908,000
Change in fair value	'	-2,328,000	829,000
Conversion to equity	-3,409,000	'	'
Balance at	'	$3,409,000	$5,737,000

Note_4_Property_and_equipment_1

Note 4 - Property and equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation	$4,854	$4,973	$14,836	$15,313

Note_4_Property_and_equipment_2

Note 4 - Property and equipment (Details) - Property and Equipment (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property and Equipment [Abstract]	'	'
Machines and equipment	$233,793	$233,793
Office and computer equipment	179,349	179,349
Software	41,872	41,872
Furniture and fixtures	25,679	25,679
Vehicles	'	22,531
Other assets	2,446	2,446
Total	483,139	505,670
Accumulated depreciation	-465,133	-472,828
Net property and equipment	$18,006	$32,842

Note_5_Intangible_assets_Detai

Note 5 - Intangible assets (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Disclosure Text Block [Abstract]	'	'	'	'
Amortization of Intangible Assets	$76,689	$76,689	$230,067	$230,067

Note_5_Intangible_assets_Detai1

Note 5 - Intangible assets (Details) - Intangible Assets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Intangible Assets [Abstract]	'	'
Patents, at cost	$3,502,135	$3,502,135
Less accumulated amortization	-2,505,177	-2,275,110
Net intangible assets	$996,958	$1,227,025

Note_6_Accrued_expenses_Detail

Note 6 - Accrued expenses (Details) - Accrued Expenses (USD $)	Sep. 30, 2013	Dec. 31, 2012
Note 6 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued executive severance	$400,000	$542,269
Accrued clinical expenses	206,489	'
Accrued board of director fees	25,333	'
Accrued other	83,619	53,528
	833,641	721,916
Audit and Tax Preparation [Member]	'	'
Note 6 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	73,700	102,600
Legal and Professional Fees [Member]	'	'
Note 6 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	$44,500	$23,519

Note_7_Promissory_notes_Detail

Note 7 - Promissory notes (Details) (USD $)	1 Months Ended
	Aug. 31, 2013	Jul. 09, 2013	Sep. 30, 2013	Jul. 09, 2013	Jul. 09, 2013	Jul. 09, 2013
			Chief Executive Officer [Member]	Chief Executive Officer [Member]	David N. Nemelka [Member]	Interest Accrued on Unpaid Balance [Member]
Note 7 - Promissory notes (Details) [Line Items]	'	'	'	'	'	'
Short-term Debt	'	$360,000	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	18.00%	'	'	'	25.00%
Due to Related Parties	'	'	36,450	35,000	100,000	'
Repayments of Related Party Debt	325,000	'	'	'	'	'
Interest Expense, Related Party	$10,664	'	'	'	'	'

Note_8_18_Senior_Secured_Conve1

Note 8 - 18% Senior Secured Convertible Promissory Notes (Details) (USD $)	0 Months Ended	1 Months Ended			3 Months Ended	9 Months Ended
	Mar. 08, 2013	Jul. 31, 2013	Feb. 25, 2013	Feb. 28, 2013	Sep. 30, 2013	Sep. 30, 2013	Jul. 25, 2013	Jul. 09, 2013
Note 8 - 18% Senior Secured Convertible Promissory Notes (Details) [Line Items]	'	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	18.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$0.20	$0.20	'	'	'	'	'	'
Debt Conversion, Original Debt, Amount	$4,000,000	'	'	'	'	$64,500	'	'
Debt Instrument, Convertible, Terms of Conversion Feature	'20%	'	'	'	'	'	'	'
Secured Debt	'	2,186,906	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	'	10,934,533	'	'	'	322,500	'	'
Warrants Issued (in Shares)	'	1,988,095	2,000,000	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	0.8	0.35	0.35	'	'	0.55	'
Warrants Term	'	'5 years	'	'5 years	'	'	'	'
Gains (Losses) on Extinguishment of Debt	'	-1,073,572	'	'	-1,073,572	-1,073,572	'	'
Debt Instrument, Unamortized Discount	2,000,000	'	'	'	2,000,000	2,000,000	'	'
Debt Instrument, Increase, Accrued Interest	'	'	'	'	-421,060	-2,178,390	'	'
Board of Directors Chairman [Member]	'	'	'	'	'	'	'	'
Note 8 - 18% Senior Secured Convertible Promissory Notes (Details) [Line Items]	'	'	'	'	'	'	'	'
Warrants Issued (in Shares)	'	'	'	'	'	58,635	'	'
Secured Convertible Promissory Notes [Member]	'	'	'	'	'	'	'	'
Note 8 - 18% Senior Secured Convertible Promissory Notes (Details) [Line Items]	'	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	18.00%	'	'	'	'	'	'	'
Senior Secured Notes [Member]	'	'	'	'	'	'	'	'
Note 8 - 18% Senior Secured Convertible Promissory Notes (Details) [Line Items]	'	'	'	'	'	'	'	'
Notes Issued	$2,000,000	'	'	'	'	'	'	'

Note_9_Notes_Payable_Related_P2

Note 9 - Notes Payable, Related Parties (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
					Note Payable To HealthTronics [Member]	Note Payable To HealthTronics [Member]
Note 9 - Notes Payable, Related Parties (Details) [Line Items]	'	'	'	'	'	'
Related Party Transaction, Rate	'	'	6.00%	'	'	'
Interest Payable, Current	'	'	'	'	$81,864	$81,864
Interest Expense, Debt	$81,864	$81,864	$242,904	$242,903	'	'

Note_9_Notes_Payable_Related_P3

Note 9 - Notes Payable, Related Parties (Details) - Notes Payable (USD $)	Sep. 30, 2013	Dec. 31, 2012
Note 9 - Notes Payable, Related Parties (Details) - Notes Payable [Line Items]	'	'
Notes payable, unsecured, payable to HealthTronics, Inc., a shareholder of the Company	$5,372,743	$5,372,743
Non-current portion	5,372,743	5,372,743
Unsecured Debt [Member]	'	'
Note 9 - Notes Payable, Related Parties (Details) - Notes Payable [Line Items]	'	'
Notes payable, unsecured, payable to HealthTronics, Inc., a shareholder of the Company	5,372,743	5,372,743
Non-current portion	$5,372,743	$5,372,743

Note_10_Income_taxes_Details

Note 10 - Income taxes (Details) (USD $)	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Operating Loss Carryforwards	$53,648,527

Note_11_Equity_Transactions_De

Note 11 - Equity Transactions (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Feb. 25, 2013

Sep. 30, 2013

Jul. 25, 2013

Jul. 31, 2013

Feb. 25, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2013

Nov. 27, 2012

Oct. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Feb. 25, 2013

Subsequent Event [Member]

Consulting Fees [Member]

Consulting Fees [Member]

Note Payable to Prides Capital Fund I LP and NightWatch Capital Partners II LP [Member]

Note 11 - Equity Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

675,000

3,006,818

'

'

100,000

'

400,000

'

201,979

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

'

$405,000

$1,653,750

'

'

'

'

$405,000

'

$121,187

'

'

'

Warrants Price Per Unit (in Dollars per Item)

'

'

0.8

'

'

'

'

'

'

0.6

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

0.35

'

0.55

0.8

0.35

0.35

'

'

'

0.85

'

'

0.35

Share Price (in Dollars per share)

'

'

'

'

'

'

'

'

$0.25

$1.40

'

'

'

Warrants Callable Period

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

1,503,409

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance of Private Placement Net (in Dollars)

'

'

1,517,450

'

'

'

'

'

'

'

'

'

'

Warrant Exercisable Term

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Warrants Issued

'

'

'

1,988,095

2,000,000

'

'

'

'

'

'

'

2,000,000

Warrants, Vested During Period

300,000

'

'

'

300,000

'

'

'

'

'

'

'

'

Warrants Vesting Contingent Upon Captial Raise Completion

1,700,000

'

'

'

1,700,000

'

'

'

'

'

'

'

'

Capital Raise Threshold for Vesting of Warrants (in Dollars)

5,000,000

'

'

'

5,000,000

4,000,000

'

'

'

'

'

'

'

Warrants Expired

1,700,000

'

'

'

1,700,000

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

35,000

'

'

'

'

'

'

'

Number of Warrants To be Issued

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

Warrants Term

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

'

'

'

'

542,000

934,000

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services (in Dollars)

'

'

'

'

'

'

'

($751,587)

'

'

$313,880

$622,760

'

Note_12_Warrants_Details

Note 12 - Warrants (Details) (USD $)	0 Months Ended	1 Months Ended
	Feb. 25, 2013	Jul. 31, 2013	Feb. 25, 2013	Jul. 25, 2013	Feb. 28, 2013
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding [Abstract]	'	'	'	'	'
Warrants Issued	'	1,988,095	2,000,000	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	0.35	0.8	0.35	0.55	0.35
Warrants, Vested During Period	300,000	'	300,000	'	'
Warrants Vesting Contingent Upon Captial Raise Completion	1,700,000	'	1,700,000	'	'
Capital Raise Threshold for Vesting of Warrants (in Dollars)	$5,000,000	'	$5,000,000	'	$4,000,000
Warrants Expired	1,700,000	'	1,700,000	'	'
Warrants and Rights Outstanding (in Dollars)	$300,000	'	$300,000	'	'

Note_12_Warrants_Details_Warra

Note 12 - Warrants (Details) - Warrant Activity

0 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Feb. 25, 2013

Jul. 31, 2013

Feb. 25, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class D Warrants [Member]

Class E Warrants [Member]

Class E Warrants [Member]

Class E Warrants [Member]

Class E Warrants [Member]

Class F Warrants [Member]

Class F Warrants [Member]

Class G Warrants [Member]

Class H Warrants [Member]

Class I Warrants [Member]

Outstanding as of

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding

'

'

'

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,950,167

3,576,737

3,576,737

3,576,737

3,576,737

2,000,000

'

'

'

'

Issued

'

1,988,095

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

1,503,409

1,988,095

675,000

Expired

1,700,000

'

1,700,000

'

'

'

'

'

'

'

'

-1,950,167

'

'

'

'

-1,700,000

'

'

'

'

Outstanding

'

'

'

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

1,106,627

'

3,576,737

3,576,737

3,576,737

3,576,737

300,000

2,000,000

1,503,409

1,988,095

675,000

Note_12_Warrants_Details_Warra1

Note 12 - Warrants (Details) - Warrant exercise price per share and expiration date

Jul. 31, 2013

Jul. 25, 2013

Feb. 28, 2013

Feb. 25, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Class A Warrants [Member]

Class B Warrants [Member]

Class D Warrants [Member]

Class E Warrants [Member]

Class F Warrants [Member]

Class G Warrants [Member]

Class H Warrants [Member]

Class I Warrants [Member]

Note 12 - Warrants (Details) - Warrant exercise price per share and expiration date [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price/share

0.8

0.55

0.35

0.35

4

8

2

4

0.35

0.8

0.8

0.85

Expiration Date

'

'

'

'

30-Sep-14

30-Sep-14

31-Jan-13

30-Apr-16

28-Feb-18

31-Jul-18

31-Jul-18

30-Sep-18

Note_13_Commitments_and_contin1

Note 13 - Commitments and contingencies (Details) (USD $)	1 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2013	Jul. 25, 2013	Feb. 28, 2013	Nov. 27, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	'	'	'	4,000,000	'	'	'	'	'
Share Price (in Dollars per share)	'	'	'	$0.25	'	'	'	'	'
Aggregate Sales Price for Common Stock	'	'	'	$1,000,000	'	'	'	'	'
Minimum Installment Amount of Purchase Price	'	'	'	100,000	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	'	'	'	'	1,517,450	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	675,000	3,006,818	100,000	'	'	'	400,000	'	'
Operating Leases, Rent Expense, Net	'	'	'	'	22,531	68,462	76,508	238,712	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	10,106	'	'	'	10,106	'	10,106	'	6,468
Capital Leases, Balance Sheet, Assets by Major Class, Net	4,446	'	'	'	4,446	'	4,446	'	8,085
Pro Forma [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Cash	'	'	'	100,000	'	'	'	'	'
Scenario, Forecast [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	3,600,000	'	'	'	3,600,000	'	3,600,000	'	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	900,000	'	'	'	900,000	'	900,000	'	'
Subscription Agreement [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	'	'	'	'	100,000	'	'
On Or Before January 31, 2013 [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	'	'	'	50,000	'	'	'	'	'
On Or Before February 15, 2013 [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	'	'	'	50,000	'	'	'	'	'
On Or Before May 27, 2014 [Member]	'	'	'	'	'	'	'	'	'
Note 13 - Commitments and contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	'	'	'	$900,000	'	'	'	'	'

Note_14_401k_plan_Details

Note 14 - 401(k) plan (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'	'
Defined Contribution Plan, Cost Recognized	$0	$9,664

Note_15_Stockbased_compensatio2

Note 15 - Stock-based compensation (Details) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

Feb. 21, 2013

Mar. 08, 2012

Feb. 25, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Feb. 25, 2013

Feb. 25, 2013

Feb. 25, 2013

Feb. 25, 2013

Feb. 25, 2013

Mar. 08, 2012

Sep. 30, 2013

Feb. 21, 2013

Dec. 31, 2012

Sep. 03, 2013

Feb. 21, 2013

Feb. 25, 2013

Options Vesting Upon Company Completing $5.0 Million Gross Proceeds [Member]

Options Vesting Upon Company Completing $1.0 Million Gross Proceeds [Member]

Options Vesting Upon Company Completing $1.0 Million Gross Proceeds [Member]

Upon Events Tied To Clinical Trial Plan for DermaPACE Device [Member]

Upon Achieveing All Milestones During Initial Two Year Term and the Term is Not Extended by Company [Member]

Each Member of Medical Advisory Board [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

New Member of Board of Directors [Member]

Each Member of Medical Advisory Board [Member]

Minimum [Member]

Minimum [Member]

Note 15 - Stock-based compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'10 years

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'5 years

'5 years 73 days

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

2,243,644

'

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

8,500,000

5,000,000

'

50,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

100,000

'

4,593,644

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$0.35

'

$0.35

$0.65

'

$0.35

'

'

'

'

'

'

'

'

'

$0.44

'

'

'

$0.65

$0.35

$0.35

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$0.22

$0.27

$0.21

'

'

'

'

$0.63

'

'

'

'

'

'

'

'

'

'

'

$0.60

'

'

Allocated Share-based Compensation Expense (in Dollars)

$499,621

'

$465,000

'

'

'

'

$63,000

'

$27,250

'

'

'

'

'

'

'

'

'

$60,000

'

'

Share-Based Compensation Arrangement, By Share-Based Payment Award, Options, Cancel In Period

1,113,644

'

'

'

'

43,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price Per Share (in Dollars per share)

$2.92

'

'

'

'

$2.87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod

'

'

375,000

125,000

137,500

1,180,386

'

'

'

'

375,000

375,000

'

375,000

750,000

'

'

'

'

'

'

'

Cash Receipt For Option Vesting Threshold (in Dollars)

'

'

'

'

'

'

'

'

'

'

5,000,000

1,000,000

250,000

'

'

'

'

'

'

'

'

'

Share-based Compensation (in Dollars)

'

'

'

$175,987

'

'

$217,686

$683,382

$719,732

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'7 years 36 days

'

'6 years 219 days

'

'

'

'

'

'

'

'

'

'

'

'

Note_15_Stockbased_compensatio3

Note 15 - Stock-based compensation (Details) - Fair Value Assumption	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Fair Value Assumption [Abstract]	'	'
Weighted average expected life in years	'5 years	'5 years 73 days
Weighted average risk free interest rate	1.68%	0.95%
Weighted average volatility	149.00%	75.00%
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note_15_Stockbased_compensatio4

Note 15 - Stock-based compensation (Details) - Option Activity (USD $)	1 Months Ended		3 Months Ended
	Feb. 21, 2013	Feb. 25, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Option Activity [Abstract]	'	'	'	'	'
Outstanding number	'	'	8,266,830	8,604,330	5,229,330
Outstanding weighted average exercise price per share (in Dollars per share)	'	'	$1.17	$1.14	$2.25
Granted number	'	'	100,000	'	4,593,644
Granted weighted average exercise price per share (in Dollars per share)	$0.35	$0.35	$0.65	'	$0.35
Exercised number	'	'	'	-108,334	'
Exercised weighted average exercise price per share (in Dollars per share)	'	'	'	$0.35	'
Forfeited or expired number	'	'	'	'	-1,113,644
Forfeited or expired weighted average exercise price per share (in Dollars per share)	'	'	'	'	$2.92
Forfeited or expired number	'	'	'	-229,166	-105,000
Forfeited or expired weighted average exercise price per share (in Dollars per share)	'	'	'	($0.34)	$2.93
Exercisable	'	'	4,887,738	'	'
Exercisable (in Dollars per share)	'	'	$1.76	'	'
Outstanding number	'	'	8,366,830	8,266,830	8,604,330
Outstanding weighted average exercise price per share (in Dollars per share)	'	'	$1.17	$1.17	$1.14

Note_15_Stockbased_compensatio5

Note 15 - Stock-based compensation (Details) - Nonvested Options Activity (USD $)	1 Months Ended		3 Months Ended
	Feb. 21, 2013	Feb. 25, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Nonvested Options Activity [Abstract]	'	'	'	'	'
Outstanding number	'	'	3,504,092	3,870,758	508,750
Outstanding weighted average exercise price per share (in Dollars per share)	'	'	$0.34	$0.33	$0.66
Granted number number	'	'	100,000	'	4,593,644
Granted weighted average exercise price per share (in Dollars per share)	'	'	$0.65	'	$0.35
Vested number	'	-375,000	-125,000	-137,500	-1,180,386
Vested weighted average exercise price per share (in Dollars per share)	'	'	$0.59	$0.24	$0.41
Forfeited or expired number	-1,113,644	'	'	'	-43,750
Forfeited or expired weighted average exercise price per share (in Dollars per share)	$2.92	'	'	'	$2.87
Forfeited or expired number	'	'	'	-229,166	-7,500
Forfeited or expired weighted average exercise price per share (in Dollars per share)	'	'	'	$0.34	$5.25
Outstanding number	'	'	3,479,092	3,504,092	3,870,758
Outstanding weighted average exercise price per share (in Dollars per share)	'	'	$0.34	$0.34	$0.33

Note_16_Changes_in_other_compr2

Note 16 - Changes in other comprehensive loss (Details) - Other Comprehensive Loss (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'	'
Other comprehensive income/loss	$7,312	$9,141	$6,191	'	$7,312	'	$13,116
Other comprehensive loss before reclassifications	-1,829	'	-6,925	4,623	-5,804	3,589	'
Amounts reclassified from AOCI	'	2,950	'	'	'	'	'
Net change in other comprehensive loss	'	'	-6,925	'	'	'	'
Currency Translations [Member]	'	'	'	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'	'
Other comprehensive income/loss	7,312	9,141	6,191	'	7,312	'	13,116
Other comprehensive loss before reclassifications	-1,829	'	-6,925	'	'	'	'
Amounts reclassified from AOCI	'	2,950	'	'	'	'	'
Net change in other comprehensive loss	'	'	($6,925)	'	'	'	'

Note_17_Earnings_Loss_Per_Shar1

Note 17 - Earnings (Loss) Per Share (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,623,325	14,189,481	18,623,325	14,189,481